SCHEMBL8937274

SCHEMBL8937274

CCCOc1ccc(/C(=C/C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
DRD2 P14416 2/20 0.52
DRD3 P35462 2/20 0.52
KCNA5 P22460 2/20 0.52
LMNA P02545 1/20 0.51
HSD17B10 Q99714 2/20 0.49
HPGD P15428 1/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
CYP1A2 P05177 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937268 1.00 ALDH1A1 (0.55) ALDH1A1L3MBTL1DRD2DRD3KCNA5
SCHEMBL8937276 1.00 ALDH1A1 (0.55) ALDH1A1L3MBTL1DRD2DRD3KCNA5
SCHEMBL8937326 0.92 ALDH1A1 (0.51) ALDH1A1L3MBTL1DRD3KCNA5LMNA
SCHEMBL8937330 0.92 ALDH1A1 (0.51) ALDH1A1L3MBTL1DRD3KCNA5LMNA
SCHEMBL8937673 0.92 ALDH1A1 (0.51) ALDH1A1L3MBTL1DRD3KCNA5LMNA
SCHEMBL8937624 0.92 ALDH1A1 (0.53) ALDH1A1L3MBTL1DRD2DRD3KCNA5
SCHEMBL8937627 0.92 ALDH1A1 (0.53) ALDH1A1L3MBTL1DRD2DRD3KCNA5
SCHEMBL8937616 0.92 ALDH1A1 (0.53) ALDH1A1L3MBTL1DRD2DRD3KCNA5
SCHEMBL8937368 0.91 ALDH1A1 (0.60) ALDH1A1L3MBTL1DRD2DRD3KCNA5
SCHEMBL8937373 0.91 ALDH1A1 (0.60) ALDH1A1L3MBTL1DRD2DRD3KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed